Vanguard Group Inc Esperion Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $5.46 Trillion
- Q3 2024
A detailed history of Vanguard Group Inc transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 13,043,077 shares of ESPR stock, worth $29.2 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,043,077
Previous 10,816,762
20.58%
Holding current value
$29.2 Million
Previous $24 Million
10.38%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding ESPR
# of Institutions
206Shares Held
128MCall Options Held
1.67MPut Options Held
930K-
Wasatch Advisors Inc Salt Lake City, UT23.3MShares$52.3 Million0.19% of portfolio
-
Black Rock Inc. New York, NY14MShares$31.3 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V89.94MShares$22.3 Million0.28% of portfolio
-
Two Seas Capital LP Rye, NY6.58MShares$14.7 Million3.65% of portfolio
-
Geode Capital Management, LLC Boston, MA4.33MShares$9.7 Million0.0% of portfolio
About Esperion Therapeutics, Inc.
- Ticker ESPR
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 66,551,600
- Market Cap $149M
- Description
- Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...